Biomune Systems, Inc. Announces a 74% Increase in Revenues

Apr 16, 2001, 01:00 ET from Biomune Systems, Inc.

    BEDFORD PARK, Ill., April 16 /PRNewswire/ -- Biomune Systems, Inc.
 (OTC Bulletin Board:   BIME)("Biomune") announces a 74% increase in revenues.
 The revenue growth, from $793,723 in 1999 to $1,381,994 in 2000, was due to
 growth in the BioPolymers segment from new customers and new products.
 Furthermore, Biomune decreased its total operating expenses from $8,531,385 in
 1999 to $6,908,882 in 2000.  This decrease was due to cost reduction
 initiatives implemented by Biomune and not having the 1999 inventory write
 down, partially offset by costs associated with the transaction with Donlar
 Corporation ("Donlar").
     During 2000, Biomune had a pretax loss of $12,663,870, compared to a
 pretax loss of $12,149,702 during 1999.  Biomune had a net loss after taxes
 and extraordinary items of $13,713,973 in 2000, compared to $12,149,702 during
 1999.  This increase in the net loss after taxes and extraordinary items was
 attributable primarily to an increase in interest expense and expenses
 associated with the Donlar transaction.
     Biomune's 10-KSB for the year ended December 31, 2000 filed today
 represents its first 10-KSB since the transaction with Donlar and the changing
 of its fiscal year to a calendar year.
 
     Biomune, with its wholly owned subsidiary, Optim Nutrition, Inc. is a
 diversified biotech and biopolymer company that has developed a wide range of
 patented protein products for use in industrial, agricultural, consumer and
 pharmaceutical markets and is engaged in the distribution and sale of biologic
 nutraceutical supplements and sports and nutrition bars.  Certain of the
 nutraceutical supplements incorporate patented natural protein technology
 derived from milk products (whey), exclusively licensed to Biomune.
 
     This press release contains forward-looking statements within the meaning
 of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
 Exchange Act of 1934.  Actual results could differ materially from those
 projected in the forward-looking statements, which involve a number of risks
 and uncertainties.  The contents of this release should be considered in
 conjunction with the warnings and cautionary statements contained in Biomune's
 most recent filings with the Securities and Exchange Commission on Forms
 10-QSB and 10-KSB and current reports on Form 8-K.
     For further information contact Larry P. Koskan of Biomune Systems, Inc.
 at 708-563-9200.
 
 

SOURCE Biomune Systems, Inc.
    BEDFORD PARK, Ill., April 16 /PRNewswire/ -- Biomune Systems, Inc.
 (OTC Bulletin Board:   BIME)("Biomune") announces a 74% increase in revenues.
 The revenue growth, from $793,723 in 1999 to $1,381,994 in 2000, was due to
 growth in the BioPolymers segment from new customers and new products.
 Furthermore, Biomune decreased its total operating expenses from $8,531,385 in
 1999 to $6,908,882 in 2000.  This decrease was due to cost reduction
 initiatives implemented by Biomune and not having the 1999 inventory write
 down, partially offset by costs associated with the transaction with Donlar
 Corporation ("Donlar").
     During 2000, Biomune had a pretax loss of $12,663,870, compared to a
 pretax loss of $12,149,702 during 1999.  Biomune had a net loss after taxes
 and extraordinary items of $13,713,973 in 2000, compared to $12,149,702 during
 1999.  This increase in the net loss after taxes and extraordinary items was
 attributable primarily to an increase in interest expense and expenses
 associated with the Donlar transaction.
     Biomune's 10-KSB for the year ended December 31, 2000 filed today
 represents its first 10-KSB since the transaction with Donlar and the changing
 of its fiscal year to a calendar year.
 
     Biomune, with its wholly owned subsidiary, Optim Nutrition, Inc. is a
 diversified biotech and biopolymer company that has developed a wide range of
 patented protein products for use in industrial, agricultural, consumer and
 pharmaceutical markets and is engaged in the distribution and sale of biologic
 nutraceutical supplements and sports and nutrition bars.  Certain of the
 nutraceutical supplements incorporate patented natural protein technology
 derived from milk products (whey), exclusively licensed to Biomune.
 
     This press release contains forward-looking statements within the meaning
 of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
 Exchange Act of 1934.  Actual results could differ materially from those
 projected in the forward-looking statements, which involve a number of risks
 and uncertainties.  The contents of this release should be considered in
 conjunction with the warnings and cautionary statements contained in Biomune's
 most recent filings with the Securities and Exchange Commission on Forms
 10-QSB and 10-KSB and current reports on Form 8-K.
     For further information contact Larry P. Koskan of Biomune Systems, Inc.
 at 708-563-9200.
 
 SOURCE  Biomune Systems, Inc.